These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2422935)

  • 1. Lethal accumulation of procainamide metabolite in severe renal insufficiency.
    Vlasses PH; Ferguson RK; Rocci ML; Raja RM; Porter RS; Greenspan AM
    Am J Nephrol; 1986; 6(2):112-6. PubMed ID: 2422935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torsades de pointes due to n-acetylprocainamide.
    Stevenson WG; Weiss J
    Pacing Clin Electrophysiol; 1985 Jul; 8(4):528-31. PubMed ID: 2410877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging and renal clearance of procainamide and acetylprocainamide.
    Reidenberg MM; Camacho M; Kluger J; Drayer DE
    Clin Pharmacol Ther; 1980 Dec; 28(6):732-5. PubMed ID: 6160015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of desethyl procainamide in patients: a new metabolite of procainamide.
    Ruo TI; Morita Y; Atkinson AJ; Henthorn T; Thenot JP
    J Pharmacol Exp Ther; 1981 Feb; 216(2):357-62. PubMed ID: 6162026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia.
    Somberg J; Wynn J; Miura D; Torres V; Williams S; Keefe D
    Angiology; 1986 Dec; 37(12 Pt 2):972-81. PubMed ID: 2433972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma concentrations of desethyl N-acetylprocainamide in patients treated with procainamide and N-acetylprocainamide.
    Ruo TI; Thenot JP; Stec GP; Atkinson AJ
    Ther Drug Monit; 1981; 3(3):231-7. PubMed ID: 6172888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of procainamide and N-acetylprocainamide in patients undergoing continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ; Pitterle ME
    Clin Pharm; 1985; 4(6):669-72. PubMed ID: 2416503
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
    Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML
    Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome.
    Kluger J; Drayer DE; Reidenberg MM; Lahita R
    Ann Intern Med; 1981 Jul; 95(1):18-23. PubMed ID: 6166229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition study of procainamide and N-acetylprocainamide during subacute administration in rats.
    Kamath BL; Lai CM; Krasula RW; Stampfli HF; Gupta SD; Yacobi A
    Toxicol Appl Pharmacol; 1982 Jan; 62(1):158-66. PubMed ID: 6175050
    [No Abstract]   [Full Text] [Related]  

  • 19. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsade de pointes associated with elevated N-acetylprocainamide levels.
    Stratmann HG; Walter KE; Kennedy HL
    Am Heart J; 1985 Feb; 109(2):375-7. PubMed ID: 2578241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.